RecruitingNCT02143986

Glycosylated Ferritin in Macrophagic Activation Syndromes

Glycosylated Ferritin in Differential Diagnosis of Still's Disease, Sepsis and Other Macrophagic Activation Syndromes.


Sponsor

Brugmann University Hospital

Enrollment

60 participants

Start Date

May 1, 2014

Study Type

OBSERVATIONAL

Conditions

Summary

In healthy subjects, from 50 to 80 % of the serum ferritin is glycosylated \[1, 2\] . A decrease in the percentage of ferritin glycosylation can be observed in inflammatory diseases, malignancies, infections, or liver disease but is rarely less than 20% \[3 , 4\] . Percentage of glycosylated ferritin below 20% have been described in patients with adult Still's disease and haemophagocytosis lymphohistiocytic syndromes (HLH). The glycosylated ferritin has been included in the diagnostic criteria for Still's disease in adults. A cut-off of less than 20 % has a sensitivity and specificity of 72 and 69 % respectively , and 35 and 94 % when combined with a total ferritin level greater than 5 times normal value. This parameter was also suggested to be a more specific marker to confirm a diagnosis of HLH than a high ferritin level ( \> 500μg / L). However, several limitations of this parameter were highlighted, some conditions making its interpretation difficult : particularly in cases of major hepatic cytolysis and severe sepsis (miliary tuberculosis, lymphoma and disease Adult Still). It is not always possible to distinguish severe sepsis, HLH syndrome and Still's disease. A fine analysis of various glycoforms components of ferritin could be used to distinguish different subgroups of patients. Few data are available on the mechanism of secretion and glycosylation of ferritin, but the investigators assume that the glycosylation patterns of ferritin may vary between different disease states and reflect distinct underlying pathophysiological mechanisms.


Eligibility

Max Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This study is measuring a specific form of a blood protein called glycosylated ferritin to find out whether it can reliably help diagnose and tell apart macrophage activation syndrome (MAS) — a life-threatening overreaction of the immune system — from other serious conditions that also cause very high ferritin levels in the blood. These other conditions include Still's disease (a severe inflammatory disorder that can affect the joints and organs), sepsis (a life-threatening response to infection), blood cancers like leukemia and lymphoma, and significant liver disease. Accurately identifying MAS early is critical because it requires very different treatment from other causes. **You may be eligible if...** - You are suspected of having sepsis, macrophage activation syndrome, Still's disease, or another condition associated with a very high ferritin level (such as a blood cancer, liver inflammation, or undiagnosed fever illness) **You may NOT be eligible if...** - Your ferritin level is within the normal range, indicating no suspected inflammatory or underlying condition causing an elevation Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Brugmann University Hospital

Brussels, Belgium

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02143986


Related Trials